S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.18 (-1.61%)
AAPL   120.19 (-1.53%)
MSFT   227.10 (-0.20%)
FB   258.10 (+1.05%)
GOOGL   2,034.55 (+1.15%)
TSLA   621.00 (-4.93%)
AMZN   2,979.87 (-0.84%)
NVDA   495.50 (-3.26%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.40 (-5.29%)
NIO   39.28 (-5.42%)
AMD   77.77 (-3.82%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.28 (-1.81%)
BAC   36.50 (+0.22%)
S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.18 (-1.61%)
AAPL   120.19 (-1.53%)
MSFT   227.10 (-0.20%)
FB   258.10 (+1.05%)
GOOGL   2,034.55 (+1.15%)
TSLA   621.00 (-4.93%)
AMZN   2,979.87 (-0.84%)
NVDA   495.50 (-3.26%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.40 (-5.29%)
NIO   39.28 (-5.42%)
AMD   77.77 (-3.82%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.28 (-1.81%)
BAC   36.50 (+0.22%)
S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.18 (-1.61%)
AAPL   120.19 (-1.53%)
MSFT   227.10 (-0.20%)
FB   258.10 (+1.05%)
GOOGL   2,034.55 (+1.15%)
TSLA   621.00 (-4.93%)
AMZN   2,979.87 (-0.84%)
NVDA   495.50 (-3.26%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.40 (-5.29%)
NIO   39.28 (-5.42%)
AMD   77.77 (-3.82%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.28 (-1.81%)
BAC   36.50 (+0.22%)
S&P 500   3,768.47 (-1.34%)
DOW   30,924.14 (-1.11%)
QQQ   304.18 (-1.61%)
AAPL   120.19 (-1.53%)
MSFT   227.10 (-0.20%)
FB   258.10 (+1.05%)
GOOGL   2,034.55 (+1.15%)
TSLA   621.00 (-4.93%)
AMZN   2,979.87 (-0.84%)
NVDA   495.50 (-3.26%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.40 (-5.29%)
NIO   39.28 (-5.42%)
AMD   77.77 (-3.82%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.28 (-1.81%)
BAC   36.50 (+0.22%)
Log in
NASDAQ:TLSA

Tiziana Life Sciences Competitors

$2.79
-0.25 (-8.22 %)
(As of 03/4/2021 03:59 PM ET)
Add
Compare
Today's Range
$2.74
Now: $2.79
$2.92
50-Day Range
$2.88
MA: $3.67
$4.73
52-Week Range
$0.62
Now: $2.79
$12.17
Volume3,155 shs
Average Volume1.47 million shs
Market Capitalization$179.17 million
P/E RatioN/A
Dividend YieldN/A
Beta1.41

Competitors

Tiziana Life Sciences (NASDAQ:TLSA) Vs. ESPR, COLL, DYN, VBIV, PRVB, and GOSS

Should you be buying TLSA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Tiziana Life Sciences, including Esperion Therapeutics (ESPR), Collegium Pharmaceutical (COLL), Dyne Therapeutics (DYN), VBI Vaccines (VBIV), Provention Bio (PRVB), and Gossamer Bio (GOSS).

Tiziana Life Sciences (NASDAQ:TLSA) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Risk and Volatility

Tiziana Life Sciences has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500.

Profitability

This table compares Tiziana Life Sciences and Esperion Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tiziana Life SciencesN/AN/AN/A
Esperion Therapeutics-46.15%-629.88%-41.43%

Analyst Recommendations

This is a summary of current recommendations and price targets for Tiziana Life Sciences and Esperion Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tiziana Life Sciences00203.00
Esperion Therapeutics23312.33

Tiziana Life Sciences currently has a consensus price target of $9.50, indicating a potential upside of 240.50%. Esperion Therapeutics has a consensus price target of $52.8889, indicating a potential upside of 92.46%. Given Tiziana Life Sciences' stronger consensus rating and higher probable upside, research analysts clearly believe Tiziana Life Sciences is more favorable than Esperion Therapeutics.

Earnings and Valuation

This table compares Tiziana Life Sciences and Esperion Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life SciencesN/AN/A$-9,320,000.00($0.03)-93.00
Esperion Therapeutics$148.36 million5.18$-97,170,000.00($3.59)-7.65

Tiziana Life Sciences has higher earnings, but lower revenue than Esperion Therapeutics. Tiziana Life Sciences is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Tiziana Life Sciences beats Esperion Therapeutics on 7 of the 12 factors compared between the two stocks.

Tiziana Life Sciences (NASDAQ:TLSA) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Risk and Volatility

Tiziana Life Sciences has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Profitability

This table compares Tiziana Life Sciences and Collegium Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tiziana Life SciencesN/AN/AN/A
Collegium Pharmaceutical5.71%12.64%3.15%

Analyst Recommendations

This is a summary of current recommendations and price targets for Tiziana Life Sciences and Collegium Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tiziana Life Sciences00203.00
Collegium Pharmaceutical11202.25

Tiziana Life Sciences currently has a consensus price target of $9.50, indicating a potential upside of 240.50%. Collegium Pharmaceutical has a consensus price target of $25.00, indicating a potential upside of 14.78%. Given Tiziana Life Sciences' stronger consensus rating and higher probable upside, research analysts clearly believe Tiziana Life Sciences is more favorable than Collegium Pharmaceutical.

Earnings and Valuation

This table compares Tiziana Life Sciences and Collegium Pharmaceutical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life SciencesN/AN/A$-9,320,000.00($0.03)-93.00
Collegium Pharmaceutical$296.70 million2.55$-22,720,000.00($0.68)-32.03

Tiziana Life Sciences has higher earnings, but lower revenue than Collegium Pharmaceutical. Tiziana Life Sciences is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Tiziana Life Sciences (NASDAQ:TLSA) and Dyne Therapeutics (NASDAQ:DYN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Profitability

This table compares Tiziana Life Sciences and Dyne Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tiziana Life SciencesN/AN/AN/A
Dyne TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Tiziana Life Sciences and Dyne Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tiziana Life Sciences00203.00
Dyne Therapeutics00503.00

Tiziana Life Sciences currently has a consensus price target of $9.50, indicating a potential upside of 240.50%. Dyne Therapeutics has a consensus price target of $34.25, indicating a potential upside of 117.18%. Given Tiziana Life Sciences' higher probable upside, research analysts clearly believe Tiziana Life Sciences is more favorable than Dyne Therapeutics.

Insider and Institutional Ownership

59.4% of Dyne Therapeutics shares are owned by institutional investors. 1.8% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Tiziana Life Sciences and Dyne Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life SciencesN/AN/A$-9,320,000.00($0.03)-93.00
Dyne TherapeuticsN/AN/AN/AN/AN/A

Summary

Dyne Therapeutics beats Tiziana Life Sciences on 3 of the 4 factors compared between the two stocks.

Tiziana Life Sciences (NASDAQ:TLSA) and VBI Vaccines (NASDAQ:VBIV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Earnings and Valuation

This table compares Tiziana Life Sciences and VBI Vaccines' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life SciencesN/AN/A$-9,320,000.00($0.03)-93.00
VBI Vaccines$2.22 million333.64$-54,810,000.00($0.46)-6.65

Tiziana Life Sciences has higher earnings, but lower revenue than VBI Vaccines. Tiziana Life Sciences is trading at a lower price-to-earnings ratio than VBI Vaccines, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Tiziana Life Sciences has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500.

Profitability

This table compares Tiziana Life Sciences and VBI Vaccines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tiziana Life SciencesN/AN/AN/A
VBI Vaccines-2,837.73%-36.69%-28.29%

Analyst Recommendations

This is a summary of current recommendations and price targets for Tiziana Life Sciences and VBI Vaccines, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tiziana Life Sciences00203.00
VBI Vaccines00413.20

Tiziana Life Sciences currently has a consensus price target of $9.50, indicating a potential upside of 240.50%. VBI Vaccines has a consensus price target of $6.40, indicating a potential upside of 109.15%. Given Tiziana Life Sciences' higher probable upside, research analysts clearly believe Tiziana Life Sciences is more favorable than VBI Vaccines.

Insider and Institutional Ownership

52.1% of VBI Vaccines shares are owned by institutional investors. 10.5% of VBI Vaccines shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

VBI Vaccines beats Tiziana Life Sciences on 8 of the 14 factors compared between the two stocks.

Tiziana Life Sciences (NASDAQ:TLSA) and Provention Bio (NASDAQ:PRVB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Earnings & Valuation

This table compares Tiziana Life Sciences and Provention Bio's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life SciencesN/AN/A$-9,320,000.00($0.03)-93.00
Provention BioN/AN/A$-43,280,000.00($1.06)-10.54

Tiziana Life Sciences is trading at a lower price-to-earnings ratio than Provention Bio, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Tiziana Life Sciences has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Provention Bio has a beta of 3.34, suggesting that its stock price is 234% more volatile than the S&P 500.

Profitability

This table compares Tiziana Life Sciences and Provention Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tiziana Life SciencesN/AN/AN/A
Provention BioN/A-67.66%-62.27%

Analyst Ratings

This is a summary of current ratings and target prices for Tiziana Life Sciences and Provention Bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tiziana Life Sciences00203.00
Provention Bio00403.00

Tiziana Life Sciences currently has a consensus price target of $9.50, indicating a potential upside of 240.50%. Provention Bio has a consensus price target of $30.75, indicating a potential upside of 175.29%. Given Tiziana Life Sciences' higher probable upside, analysts plainly believe Tiziana Life Sciences is more favorable than Provention Bio.

Insider & Institutional Ownership

39.4% of Provention Bio shares are held by institutional investors. 14.4% of Provention Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Tiziana Life Sciences (NASDAQ:TLSA) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Earnings & Valuation

This table compares Tiziana Life Sciences and Gossamer Bio's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life SciencesN/AN/A$-9,320,000.00($0.03)-93.00
Gossamer BioN/AN/A$-180,310,000.00($3.29)-2.93

Tiziana Life Sciences is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Tiziana Life Sciences has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

Profitability

This table compares Tiziana Life Sciences and Gossamer Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tiziana Life SciencesN/AN/AN/A
Gossamer BioN/A-64.34%-46.52%

Analyst Ratings

This is a summary of current ratings and target prices for Tiziana Life Sciences and Gossamer Bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tiziana Life Sciences00203.00
Gossamer Bio00503.00

Tiziana Life Sciences currently has a consensus price target of $9.50, indicating a potential upside of 240.50%. Gossamer Bio has a consensus price target of $22.80, indicating a potential upside of 136.51%. Given Tiziana Life Sciences' higher probable upside, analysts plainly believe Tiziana Life Sciences is more favorable than Gossamer Bio.

Insider & Institutional Ownership

72.0% of Gossamer Bio shares are held by institutional investors. 23.3% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Tiziana Life Sciences beats Gossamer Bio on 6 of the 10 factors compared between the two stocks.


Tiziana Life Sciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$27.48-0.0%$768.15 million$148.36 million-7.14Analyst Report
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.6$21.78-0.4%$760.11 million$296.70 million44.45Earnings Announcement
Insider Selling
News Coverage
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$15.77-5.8%$758.06 millionN/A0.00News Coverage
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$3.06-0.7%$745.52 million$2.22 million-18.00Earnings Announcement
Analyst Revision
Gap Up
Provention Bio logo
PRVB
Provention Bio
1.4$11.17-5.1%$744.02 millionN/A-7.50Analyst Report
Analyst Revision
News Coverage
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$9.64-0.5%$731.87 millionN/A-2.71Analyst Revision
Merus logo
MRUS
Merus
1.4$21.53-7.4%$730.66 million$31.13 million-7.01Upcoming Earnings
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.6$17.03-1.8%$730.60 million$17.26 million-4.73Upcoming Earnings
Odonate Therapeutics logo
ODT
Odonate Therapeutics
2.1$17.86-4.9%$723.05 millionN/A-4.56News Coverage
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$27.09-6.8%$722.16 million$19.56 million-19.49Decrease in Short Interest
Gap Up
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$19.62-5.0%$721.14 million$6.83 million-20.23Analyst Report
Analyst Revision
News Coverage
Akouos logo
AKUS
Akouos
1.7$18.85-10.5%$715.85 millionN/A0.00
OrganiGram logo
OGI
OrganiGram
1.2$2.81-8.9%$710.75 million$64.61 million-4.13Increase in Short Interest
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$19.35-7.2%$685.08 million$252 million-1.98Earnings Announcement
Analyst Report
Analyst Revision
BCEL
Atreca
1.7$17.40-4.4%$666.60 millionN/A-6.17Earnings Announcement
Analyst Revision
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$33.89-1.7%$658.86 million$9.64 million-5.52Analyst Report
Insider Selling
Analyst Revision
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.58-7.0%$647.20 million$59.29 million-23.87Earnings Announcement
Analyst Revision
News Coverage
Chimerix logo
CMRX
Chimerix
1.3$9.13-12.6%$643.88 million$12.52 million-16.02Earnings Announcement
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$12.94-1.9%$636.66 millionN/A-6.64Earnings Announcement
News Coverage
Ardelyx logo
ARDX
Ardelyx
1.9$6.68-2.7%$619.10 million$5.28 million-6.61Upcoming Earnings
Gap Up
IVA
Inventiva
0.0$14.96-0.2%$592.79 millionN/A0.00Gap Up
IDYA
IDEAYA Biosciences
1.3$18.90-7.1%$588.38 millionN/A-10.05
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$14.70-11.0%$584.13 millionN/A0.00Upcoming Earnings
Gap Up
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.67-2.1%$580.14 million$143.01 million-1.08
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$31.53-2.1%$577.55 million$12.69 million-15.16Upcoming Earnings
IVERIC bio logo
ISEE
IVERIC bio
1.5$6.02-6.8%$575.92 millionN/A-4.78Earnings Announcement
News Coverage
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.4$11.43-1.4%$555.78 million$72.96 million-3.70Upcoming Earnings
News Coverage
XBiotech logo
XBIT
XBiotech
1.2$18.08-4.0%$550.11 millionN/A1.25
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$33.12-2.1%$549.14 millionN/A-15.33
Molecular Templates logo
MTEM
Molecular Templates
2.0$10.43-4.0%$542.11 million$22.27 million-5.11Upcoming Earnings
Altimmune logo
ALT
Altimmune
1.9$13.11-9.6%$533.85 million$5.80 million-6.59Analyst Upgrade
Analyst Revision
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.18-0.0%$529.78 millionN/A-3.14News Coverage
Geron logo
GERN
Geron
1.4$1.79-4.8%$527.80 million$460,000.00-5.10Upcoming Earnings
AC Immune logo
ACIU
AC Immune
1.3$7.31-0.3%$525.86 million$111.75 million-8.12
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.5$41.80-3.5%$525.37 million$195.89 million119.43Earnings Announcement
News Coverage
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$3.32-1.5%$517.30 million$335 million-1.12Analyst Revision
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$14.30-1.0%$516.73 million$58.12 million-16.63Increase in Short Interest
News Coverage
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.4$14.35-8.3%$511.61 million$1.19 million-5.98Upcoming Earnings
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$22.40-7.1%$511.32 million$13.80 million-10.82Upcoming Earnings
SIGA
SIGA Technologies
0.3$6.55-0.2%$506.20 million$26.74 million16.38
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$6.54-4.3%$505.59 millionN/A-13.35Gap Up
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$15.93-3.2%$502.97 millionN/A-4.59Upcoming Earnings
BeyondSpring logo
BYSI
BeyondSpring
1.2$12.36-3.9%$502.58 millionN/A-6.06
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$9.75-8.5%$502.23 millionN/A-3.92Upcoming Earnings
News Coverage
Wave Life Sciences logo
WVE
Wave Life Sciences
1.8$9.34-9.6%$499.49 million$15.98 million-1.65Unusual Options Activity
News Coverage
Affimed logo
AFMD
Affimed
1.6$5.12-9.4%$494.63 million$23.96 million-8.68
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$5.68-4.9%$492.15 million$56.50 million0.00Decrease in Short Interest
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$11.51-1.7%$491.06 million$25 million-17.71Upcoming Earnings
News Coverage
89bio logo
ETNB
89bio
1.6$22.37-9.7%$487.83 millionN/A-4.43News Coverage
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8$17.60-7.5%$482.35 millionN/A-3.70Gap Down
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.